+1.54%
Today
Loading 1D prices…
Company profile
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
NYSE
Display currency
USD
Location
Hyderabad, United States
Employees
27.5K
Fiscal year end
0331
CIK
1135951
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| PTGXProtagonist Therapeutics Inc. Common Stock | $9.6B | $46M | -282.83% | -$2.05 | +2.08% | Buy |
| CYTKCytokinetics Incorporated Common Stock | $10.3B | $88M | -891.60% | -$6.54 | +0.19% | Buy |
| ABVXAbivax SA American Depositary Shares | $10.4B | — | — | -$4.83 | +2.45% | Buy |
| PRAXPraxis Precision Medicines Inc. Common Stock | $9.3B | $0.00 | — | -$13.48 | +0.13% | Buy |
| IONSIonis Pharmaceuticals Inc. Common Stock | $9B | $943.7M | -40.41% | -$2.38 | -2.61% | Buy |